Company intelligence / Profile preview

NVB Ventures

New York, New York, United States

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Nuvation Bio is a clinical-stage biopharmaceutical company focused on developing innovative therapies for oncology. Founded by David Hung, M.D., the company leverages proprietary platforms to create targeted small molecules and drug-drug conjugates (DDCs) for difficult-to-treat cancers. Its lead asset, taletrectinib, is a highly selective ROS1 inhibitor currently in pivotal development for ROS1-positive non-small cell lung cancer. Nuvation Bio aims to overcome resistance mechanisms and improve safety profiles compared to existing standards of care.

Therapeutic areas: Oncology
Modalities: Small moleculeDrug-drug conjugate
Industry: Biotech

Partnerships

AnHeart Therapeutics

Beyond the preview

Go deeper on NVB Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVB Ventures.

Explore the full profile